Moderna, Inc. (MRNA) Down 7.9% — Time to Close Shop on This One?
Moderna, Inc. (MRNA) tumbled 7.91% on the session, falling $4.26 from the prior close to settle at $49.57. The decline kept the shares firmly under pressure on the NASDAQ, erasing recent gains in a single day and signaling that sellers are firmly in command. With the stock having reached as high as $59.55 just days ago, shares now sit roughly 16.7% below that 52-week peak — a reminder of just how quickly momentum has faded and how elusive any sustained upside has been.
Trading activity reinforced the cautious tone. Volume clocked in at approximately 4.69 million shares, well below the 90-day average of roughly 11.86 million. That muted participation suggests the selloff unfolded without the kind of broad, high-conviction buying support that investors typically look for in the aftermath of a steep decline. Even so, the pullback was sharp enough to reassert near-term downside pressure — particularly with the stock still navigating a wide 52-week range of $22.28 to $59.55 that has kept price action choppy and prone to abrupt reversals.
Compared with other struggling Health Care names like Zoetis (ZTS), Natera (NTRA), and BioNTech (BNTX), MRNA's one-day percentage drop stood out as an especially steep move, with the stock losing ground considerably faster than many of its peers.
Why Moderna, Inc. Price is Moving Lower
Moderna shares remain under pressure as early March trading reflects risk-off positioning rather than any conviction in a near-term recovery. The most recent session saw the stock close at $49.83 on March 3, 2026 — down 5.71% on the day — capping a choppy stretch that has pinned the price near the low end of its late-February/early-March range of roughly $50.45 to $54.94. A sharp down day of that magnitude, particularly following volatile tape action, often signals that investors are trimming exposure to higher-uncertainty biotech names, especially those tied to shifting demand expectations and headline-driven sentiment.
The fundamentals compound those headwinds. Moderna's most recent quarterly revenue declined to $646.00 million from $973.00 million the prior quarter — a -33.6% sequential drop — while year-over-year revenue growth stands at -29.81%. Profitability remains a significant concern, with a -145.16% profit margin and EPS of -$7.26, keeping the market's attention squarely on cash burn and earnings visibility. In this environment, even modest execution shortfalls can produce outsized stock moves, as investors demand a higher risk premium for the uncertainty involved.
Broader industry dynamics add another layer of pressure. Within Health Care sector, investors have shown a clear preference for names with more defined earnings trajectories, leaving development-stage stocks exposed to waves of synchronized selling. Until revenue trends stabilize and losses begin to narrow meaningfully, caution appears well-founded — and the path of least resistance can remain to the downside.
What is the Moderna, Inc. Rating - Should I Sell?
Weiss Ratings assigns MRNA an E rating, with a current recommendation of Sell. The stock was downgraded on 2/25/2026 — a signal that Moderna, Inc.'s overall risk/reward profile has deteriorated further rather than found a floor. An E (Sell) rating reflects a judgment that downside risks outweigh the upside case once business momentum, market performance, and risk factors are weighed together.
The sub-index breakdown helps explain why shareholder outcomes have been so difficult. Moderna carries a Weak Growth Index and a Very Weak Efficiency Index, consistent with shrinking operations and poor profitability. Revenue growth of -29.81% and a profit margin of -145.16% indicate that losses are occurring at a scale capable of overwhelming even the most optimistic narratives about future products. A negative forward P/E of -7.41 further reflects expectations for continued losses, eroding the valuation floor that earnings would normally provide during periods of market stress.
Even where the fundamentals look more stable, they have offered little protection to investors. The Excellent Solvency Index points to genuine balance-sheet strength, but solid solvency alone cannot generate durable returns when the Weak Total Return Index and Weak Volatility Index indicate unfavorable price performance and an unattractive risk profile. In short, the company's financial flexibility is being more than offset by weak operating economics and inconsistent returns.
Within Health Care sector, Moderna is ranked lower than even D-rated laggards like Zoetis Inc. (ZTS, D+), Natera, Inc. (NTRA, D-), and BioNTech SE (BNTX, D-). That relative gap reinforces the cautionary signal: even among challenged names, Weiss Ratings views Moderna as carrying heavier downside risk at this time.
About Moderna, Inc.
Moderna, Inc. (MRNA) is a Health Care company in the Pharmaceuticals, Biotechnology and Life Sciences industry, focused on developing messenger RNA (mRNA) medicines for patients across the U.S., Europe, and international markets. The company built its platform around designing mRNA sequences and delivering them to cells to produce targeted proteins — an approach intended to compress early development timelines relative to traditional biologics. In practice, Moderna remains most closely identified with its respiratory vaccine franchise, reflecting a narrower commercial footprint than many large-cap peers across the Health Care sector.
Its marketed respiratory vaccines include Spikevax alongside a range of programs spanning COVID, RSV, seasonal influenza, combination respiratory vaccines, and pandemic influenza candidates. Beyond respiratory, Moderna's pipeline extends to latent virus vaccines targeting cytomegalovirus, Epstein-Barr virus, and HIV; enteric virus programs such as norovirus; and public health initiatives addressing Zika, Nipah, and Mpox, together with bacterial-disease work including Lyme vaccines. The company also develops oncology therapeutics, encompassing individualized cancer vaccine approaches such as intismeran autogene, cancer antigen therapy, T-cell engagers, and cell-therapy enhancers, as well as rare-disease programs for propionic and methylmalonic acidemia and cystic fibrosis.
Moderna's development strategy leans heavily on external partnerships and collaborations, including engagements with Merck & Co., Vertex, immatics, DARPA, BARDA, the Institute for Life Changing Medicines, the Bill & Melinda Gates Foundation, and OpenAI. Founded in 2010 and headquartered in Cambridge, Massachusetts, the company was formerly known as Moderna Therapeutics, Inc. before adopting the Moderna, Inc. name in 2018.
Investor Outlook
With an E (Sell) Weiss Rating, Moderna, Inc. (MRNA) presents a higher-risk setup. Investors may want to look for clear evidence that the recent downtrend is stabilizing and that key technical levels are holding before reassessing their positioning. It is worth monitoring Health Care sector sentiment closely, as well as any further deterioration in fundamentals that could reinforce the weak risk/reward profile the rating already implies. See full rankings of all E-rated Health Care stocks inside the Weiss Stock Screener.
--